Stock Track | Ascendis Pharma Soars 5.4% on Positive Analyst Views and Earnings Beat

Stock Track

Nov 15, 2024

Shares of Ascendis Pharma A/S (ASND) soared 5.4% in the pre-market session on Friday, riding on favorable analyst reports and better-than-expected quarterly earnings results.

Analysts from Bank of America Securities and Stifel Nicolaus reiterated their "Buy" ratings on the biopharmaceutical company, highlighting its strong growth prospects. Their positive views could have fueled investor optimism and contributed to the stock's surge.

Additionally, Ascendis Pharma reported a narrower-than-expected loss for the third quarter ended September 30. While the company posted a loss of €1.72 per share, it beat analysts' expectations of a €1.74 loss per share. The earnings beat, albeit modest, may have further boosted investor confidence in the company's performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1110739990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110739990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110739990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110739990","market":"hk","top_or_hot":-1,"title":"Stock Track | Ascendis Pharma Soars 5.4% on Positive Analyst Views and Earnings Beat","media":"Stock Track","content":"<p>Shares of Ascendis Pharma A/S (ASND) soared 5.4% in the pre-market session on Friday, riding on favorable analyst reports and better-than-expected quarterly earnings results.</p>\n\n<p>Analysts from Bank of America Securities and Stifel Nicolaus reiterated their \"Buy\" ratings on the biopharmaceutical company, highlighting its strong growth prospects. Their positive views could have fueled investor optimism and contributed to the stock's surge.</p>\n\n<p>Additionally, Ascendis Pharma reported a narrower-than-expected loss for the third quarter ended September 30. While the company posted a loss of €1.72 per share, it beat analysts' expectations of a €1.74 loss per share. The earnings beat, albeit modest, may have further boosted investor confidence in the company's performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ascendis Pharma Soars 5.4% on Positive Analyst Views and Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ascendis Pharma Soars 5.4% on Positive Analyst Views and Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-15 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ascendis Pharma A/S (ASND) soared 5.4% in the pre-market session on Friday, riding on favorable analyst reports and better-than-expected quarterly earnings results.</p>\n\n<p>Analysts from Bank of America Securities and Stifel Nicolaus reiterated their \"Buy\" ratings on the biopharmaceutical company, highlighting its strong growth prospects. Their positive views could have fueled investor optimism and contributed to the stock's surge.</p>\n\n<p>Additionally, Ascendis Pharma reported a narrower-than-expected loss for the third quarter ended September 30. While the company posted a loss of €1.72 per share, it beat analysts' expectations of a €1.74 loss per share. The earnings beat, albeit modest, may have further boosted investor confidence in the company's performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"","article_id":"1110739990","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110739990","pubTimestamp":1731681868,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ascendis Pharma A/S  soared 5.4% in the pre-market session on Friday, riding on favorable analyst reports and better-than-expected quarterly earnings results.Analysts from Bank of America Securities and Stifel Nicolaus reiterated their \"Buy\" ratings on the biopharmaceutical company, highlighting its strong growth prospects. Their positive views could have fueled investor optimism and contributed to the stock's surge.Additionally, Ascendis Pharma reported a narrower-than-expected loss f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S"},"translate_title":"由于分析师的积极观点和盈利超出预期，Ascendis Pharma股价飙升5.4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1},"content_text":"Shares of Ascendis Pharma A/S (ASND) soared 5.4% in the pre-market session on Friday, riding on favorable analyst reports and better-than-expected quarterly earnings results.\nAnalysts from Bank of America Securities and Stifel Nicolaus reiterated their \"Buy\" ratings on the biopharmaceutical company, highlighting its strong growth prospects. Their positive views could have fueled investor optimism and contributed to the stock's surge.\nAdditionally, Ascendis Pharma reported a narrower-than-expected loss for the third quarter ended September 30. While the company posted a loss of €1.72 per share, it beat analysts' expectations of a €1.74 loss per share. The earnings beat, albeit modest, may have further boosted investor confidence in the company's performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}